Abstract | OBJECTIVES: METHODS: RESULTS: Of the 126 treated patients, 123 [97.6%; 95% confidence interval (CI): 93.2-99.5)] were castrated 4 weeks after the first subcutaneous injection, and 115/119 patients (96.6%; 95% CI: 91.6-99.1) castrated at 4 weeks maintained castration at 26 weeks. Median prostate-specific antigen levels were reduced by 64.2 and 96.0% at 4 and 26 weeks, respectively. The probability of maintaining a testosterone level <20 ng/dl up to 26 weeks was 90.0% (95% CI: 85.0-95.0). The most frequently occurring treatment-related adverse events were typical of gonadotropin-releasing hormone agonist treatment (hot flushes, increased weight, erectile dysfunction and hyperhidrosis). CONCLUSIONS: This study demonstrates that triptorelin pamoate 11.25 mg administered by the subcutaneous route every 3 months is as efficacious and well tolerated as administration via the intramuscular route in men with locally advanced or metastatic prostate cancer.
|
Authors | Thiery Lebret, Mathieu Rouanne, Oleg Hublarov, Viorel Jinga, Lidiya Petkova, Rumen Kotsev, Ioanel Sinescu, Pascale Dutailly |
Journal | Therapeutic advances in urology
(Ther Adv Urol)
Vol. 7
Issue 3
Pg. 125-34
(Jun 2015)
ISSN: 1756-2872 [Print] England |
PMID | 26161143
(Publication Type: Journal Article)
|